Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: A feasibility study

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Blackledge, Matthew D ^a   Collins, David J ^a   Tunariu, Nina ^a   Orton, Matthew R ^a   Padhani, Anwar R ^b   Leach, Martin O ^a   Koh, Dow Mu ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOMATION; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CERVICAL SPINE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE PROCESSING; MALE; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE SCANNER; PILOT STUDY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; STATISTICAL MODEL; TREATMENT RESPONSE; TUMOR VOLUME; WHOLE BODY MRI; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIAL; FOLLOW UP; METASTASIS; PROCEDURES; PROSTATIC NEOPLASMS; RADIOGRAPHY; SECONDARY;

BONE NEOPLASMS; BREAST NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 84899427696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091779     Document Type: Article

References (16)

1. Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, et al. (2010) Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 39: 333-343.
2. Nakanishi K, Kobayashi M, Nakaguchi K, Kyakuno M, Hashimoto N, et al. (2007) Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 6: 147-155.
3. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, et al. (2005) Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234: 756-764. (Pubitemid 40250819)
4. Reischauer C, Froehlich JM, Koh DM, Graf N, Padevit C, et al. (2010) Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 257: 523-531.
5. Ballon D, Dyke J, Schwartz LH, Lis E, Schneider E, et al. (2000) Bone marrow segmentation in leukemia using diffusion and T (2) weighted echo planar magnetic resonance imaging. NMR Biomed 13: 321-328.
6. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, et al. (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22: 275-282. (Pubitemid 39264807)
7. Heusner TA, Hahn S, Jonkmanns C, Kuemmel S, Otterbach F, et al. (2011) Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results. Br J Radiol 84: 126-135.
8. Ohno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, et al. (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248: 643-654.
9. Komori T, Narabayashi I, Matsumura K, Matsuki M, Akagi H, et al. (2007) 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 21: 209-215. (Pubitemid 47387439)
10. Blackledge MD, Leach MO, Collins DJ, Koh DM (2011) Computed diffusion-weighted MR imaging may improve tumor detection. Radiology 261: 573-581.
11. Vezhnevets V, Konouchine V (2005) Growcut: Interactive multi-label N-D image segmentation by cellular automata [abstr]. In: Proc Graphicon: 150-156.
12. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM (2007) Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 11: iii, ix-51.
13. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, et al. (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159.
14. Collins DJ, Blackledge MD (2010) Chapter 2: Techniques and Optimization (In: 'Diffusion-Weighted MR Imaging: Applications in the Body'); Koh DMe, Thoeny HCe, editors: Springer.
15. Blackledge MD, Koh DM, Padhani AR, Stirling JJ, Taylor NJ, et al. (2012) The feasibility of evaluating treatment response of bone metastases by segmenting tumor diffusion volumes to estimate total disease burden on whole body diffusion-weighted imaging [abstr]. In: Proceedings of the International Society for Magnetic Resonance in Medicine Berkeley, Calif: International Society for Magnetic Resonance in Medicine: 255.
16. Perez-Lopez R, Blackledge MD, Lorente D, Naumann U, Mateo J, et al. (2014) Evaluation of diffusion-weighted imaging as a prognostic biomarker in castration resistant prostate cancer with bone metastases [abstr]. In: Proceedings of the International Society for Magnetic Resonance in Medicine Berkeley, Calif: International Society for Magnetic Resonance in Medicine.